Clinical validity of cerebrospinal fluid AÎ²42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Article ID	Journal	Published Year	Pages	File Type
4932760	Neurobiology of Aging	2017	18 Pages	PDF

Keywords

Biomarker-based diagnosis Biomarker development Beta-amyloid Alzheimer's disease phosphorylated tau Early diagnosis Tau Cerebrospinal fluid

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Ageing

Preview

Clinical validity of cerebrospinal fluid AÎ²42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Authors

Niklas Mattsson, Anders Lönneborg, Marina Boccardi, Kaj Blennow, Oskar Hansson, Geneva Task Force for the Roadmap of Alzheimer's Biomarkers Geneva Task Force for the Roadmap of Alzheimer's Biomarkers,